Lucid Diagnostics Inc. (LUCD): Price and Financial Metrics
GET POWR RATINGS... FREE!
LUCD Stock Price Chart Interactive Chart >
LUCD Price/Volume Stats
| Current price | $2.63 | 52-week high | $13.52 |
| Prev. close | $2.53 | 52-week low | $1.69 |
| Day low | $2.51 | Volume | 47,651 |
| Day high | $2.69 | Avg. volume | 161,861 |
| 50-day MA | $2.10 | Dividend yield | N/A |
| 200-day MA | $0.00 | Market Cap | 99.76M |
Lucid Diagnostics Inc. (LUCD) Company Bio
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. It focuses on patients with gastroesophageal reflux disease, also known as chronic heartburn, acid reflux or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. The company's lead products include EsoGuard, a laboratory developed esophageal DNA test that examines individuals DNA molecules for the presence or absence of cytosine methylation; and EsoCheck, a cell collection device that collects cells of targeted region of the esophagus. Lucid Diagnostics Inc. was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.
Latest LUCD News From Around the Web
Below are the latest news stories about Lucid Diagnostics Inc that investors may wish to consider to help them evaluate LUCD as an investment opportunity.
PAVmed Appoints Shaun O’Neil as Chief Operating OfficerNEW YORK, February 24, 2022--PAVmed appoints Shaun O’Neil as Chief Operating Officer, overseeing corporate operations and commercial activities across PAVmed and its subsidiaries. |
Evernorth Executive and Healthcare Services Industry Leader Joan Harvey Named to PAVmed Board of DirectorsNEW YORK, February 15, 2022--PAVmed appoints prominent healthcare services industry leader and president of Care Solutions for Evernorth, Joan Harvey, to its Board of Directors. |
Lucid Diagnostics to Participate in a Fireside Chat at the BTIG MedTech Digital Health, Life Science, and Diagnostics Tools ConferenceLucid Diagnostics Inc. (NASDAQ: LUCD ) ("Lucid") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (NASDAQ: PAVM , PAVMZ)) ("PAVmed"), today announced that Dr. Lishan Aklog, Chairman and CEO, will participate in a Fireside Chat at the BTIG MedTech Digital Health, Life Science, and Diagnostics Tools Conference on February 17, 2022, at 8:00 AM EST. BTIG hosted events are intended for prospective and existing BTIG clients only. To listen to the live event, please contact your BTIG representative with interest. About Lucid Diagnostics Lucid Diagnostics Inc. (NASDAQ: LUCD ) is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (NASDAQ: PAVM ). Lucid is focused on the millions of patien... |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayGood morning, investor! |
PAVmed and Lucid Diagnostics Welcome New Full-Time Investor Relations TeamNEW YORK, January 12, 2022--PAVmed and Lucid Diagnostics welcome new full-time investor relations team. |
LUCD Price Returns
| 1-mo | 32.83% |
| 3-mo | -9.31% |
| 6-mo | -41.81% |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -51.02% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...